Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelfinavir for Anemia in Myelofibrosis
NCT07281781Phase 2Recruiting
- Sponsor
- University of California, Irvine
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelfinavir in myelofibrosis (MF) and anemia, sponsored by University of California, Irvine. Primary endpoint: Change in Hepcidin Levels at 30 days. Started Sep 2025; status: recruiting.
02
Drugs
nelfinavir
03
Conditions
myelofibrosis (MF)anemia
Beyond the preview
Go deeper on NCT07281781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281781.